SCOR IN ISCHEMIC HEART DISEASE IN BLACKS

缺血性心脏病专门研究中心（SCOR）的目标是 疾病在黑人是阐明病理生理基础的过度 非裔美国人缺血性心脏病的发病率和死亡率 糖尿病患者，并制定有效的对策 来解决这个问题。SCOR将由8个研究单位组成 三个核心单位。调查范围将从基础研究， 疾病机制的临床研究，旨在影响医疗 实践在近期。研究单元I，“冠状动脉血流和心肌 供应/需求关系的黑人与NIDDM”，将测试 黑人糖尿病患者冠状动脉反应性异常假说 通过增加胰岛素的干预措施， 敏感性和改善代谢紊乱相关的 NIDDM。第二研究单元“危险分层的基因分型”将 研究ACE基因对缺血性心脏病表现的重要性 使用共享等位基因新应用研究黑人心脏病 大家庭的分析。第三研究单元，“反射控制的 NIDDM的外周循环”，将定义胰岛素 阻力调节骨骼肌的反射神经源性控制 血液循环，并有助于高血压和左室肥厚的黑人。研究 第四单元，“热休克蛋白70对缺血心肌的保护”将阐明 热休克蛋白70在缺血性脑损伤中的细胞保护作用机制 心研究单元V，“糖尿病患者中的α B-晶状体蛋白/小HSP 心脏”，将检验小的hsp单独起作用的假设，和/或 与热休克蛋白70协同作用，以延缓 缺血心肌内的不可逆损伤。第六研究组， 糖尿病性心肌病的发病机制中的高脂血症 研究游离脂肪酸升高在加重缺血性心脏病中的作用， 糖尿病心脏的损伤。第七研究单元，“基因改造 肥胖/胰岛素抵抗中的脂蛋白代谢”，将评估 纠正葡萄糖清除和脂肪代谢异常的可行性 在II型动物模型中通过肝基因转移的酸氧化 糖尿病研究单元八，“脂蛋白的遗传修饰 肥胖症/胰岛素抵抗的代谢”，将采用体细胞基因 将改变动物模型中胆固醇代谢的方法转移到 纠正与糖尿病相关的致动脉粥样硬化脂蛋白谱。 行政、生物技术和生物学的核心单位将 支持和扩大研究单位的活动。研究 在该SCOR中进行的旨在改善缺血性心脏病的药物治疗， 心脏病，并促进国家心脏的整体使命， 肺和血液研究所减少人类痛苦和死亡 可归因于心血管疾病。

The goal of this Specialized Center of Research (SCOR) for Ischemic Heart Disease in Blacks is to elucidate the pathophysiological basis for excess morbidity and mortality from ischemic heart disease in African-American persons with diabetes mellitus, and to develop effective countermeasures to address this problem. The SCOR will be comprised of 8 research units and 3 core units. Investigations will range from fundamental studies of disease mechanisms to clinical research designed to influence medical practice in the near term. Research unit I, "Coronary flow and myocardial supply/demand relationships in blacks with NIDDM", will test the hypothesis that abnormalities in coronary reactivity in black diabetics are reversible, at least in part, by interventions that increase insulin sensitivity and ameliorate the metabolic perturbations associated with NIDDM. Research unit II, "Genotyping for risk stratification", will examine the importance of the ACE gene for manifestations of ischemic heart disease in blacks using a novel application of shared allele analysis in large families. Research unit III, "Reflex control of the peripheral circulation in NIDDM", will define mechanisms by which insulin resistance modulates the reflex neurogenic control of the skeletal muscle circulation and contributes to hypertension and LVH in blacks. Research unit IV, "Protection of the ischemic myocardium by hsp70" will elucidate mechanisms of the cytoprotective function of hsp70 within the ischemic heart. Research unit V, "alpha B-crystallin/small HSP in the diabetic heart", will test the hypothesis that small hsps act alone, and/or synergistically with hsp70, to delay the onset and progression of irreversible injury within the ischemic myocardium. Research unit VI, "Hyperlipacidemia in the pathogenesis of diabetic cardiomyopathy", will examine the role of elevated free fatty acids in exacerbating ischemic injury in the diabetic heart. Research unit VII, "Genetic modification of lipoprotein metabolism in obesity/insulin resistance", will assess the feasibility of correcting abnormalities in glucose clearance and fatty acid oxidation by hepatic gene transfer in an animal model of type II diabetes. Research unit VIII, "Genetic modification of lipoprotein metabolism in obesity/insulin resistance", will employ somatic cell gene transfer methods to modify cholesterol metabolism in animal models to correct the atherogenic lipoprotein profile associated with diabetes. Core units for Administration, Biotechnology, and Histopathology will support and expand the activities of the research units. Research conducted within this SCOR seeks to improve medical therapy of ischemic heart disease, and to promote the overall mission of the National Heart, Lung and Blood Institute in reducing human suffering and death attributable to cardiovascular disorders.